[go: up one dir, main page]

DK0576478T4 - Herpes Simplex-vaccine omfattende HSV-glycoproteingD og 3-deacyleret monophosphoryl-lipid A - Google Patents

Herpes Simplex-vaccine omfattende HSV-glycoproteingD og 3-deacyleret monophosphoryl-lipid A

Info

Publication number
DK0576478T4
DK0576478T4 DK92906441T DK92906441T DK0576478T4 DK 0576478 T4 DK0576478 T4 DK 0576478T4 DK 92906441 T DK92906441 T DK 92906441T DK 92906441 T DK92906441 T DK 92906441T DK 0576478 T4 DK0576478 T4 DK 0576478T4
Authority
DK
Denmark
Prior art keywords
herpes simplex
monophosphoryl lipid
deacylated monophosphoryl
hsv glycoprotein
simplex vaccine
Prior art date
Application number
DK92906441T
Other languages
Danish (da)
English (en)
Other versions
DK0576478T3 (da
Inventor
Myriam Francotte
Jean-Paul Prieels
Moncef Slaoui
Nathalie Marie- Garcon-Johnson
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10691946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0576478(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of DK0576478T3 publication Critical patent/DK0576478T3/da
Application granted granted Critical
Publication of DK0576478T4 publication Critical patent/DK0576478T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK92906441T 1991-03-21 1992-03-17 Herpes Simplex-vaccine omfattende HSV-glycoproteingD og 3-deacyleret monophosphoryl-lipid A DK0576478T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9105992A GB9105992D0 (en) 1991-03-21 1991-03-21 Vaccine
PCT/EP1992/000592 WO1992016231A1 (en) 1991-03-21 1992-03-17 HERPES SIMPLEX VACCINE COMPRISING HSV GLYCOPROTEIN gD AND 3 dEACYLATED MONOPHOSPHORYL LIPID A

Publications (2)

Publication Number Publication Date
DK0576478T3 DK0576478T3 (da) 1995-12-04
DK0576478T4 true DK0576478T4 (da) 2001-07-23

Family

ID=10691946

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92906441T DK0576478T4 (da) 1991-03-21 1992-03-17 Herpes Simplex-vaccine omfattende HSV-glycoproteingD og 3-deacyleret monophosphoryl-lipid A

Country Status (34)

Country Link
US (1) US6027730A (no)
EP (1) EP0576478B2 (no)
JP (1) JP3530526B2 (no)
KR (1) KR100224329B1 (no)
CN (2) CN1058191C (no)
AP (1) AP298A (no)
AT (1) ATE129160T1 (no)
AU (1) AU650521B2 (no)
BR (1) BR9205745A (no)
CA (1) CA2106492C (no)
CY (1) CY1936A (no)
CZ (1) CZ280505B6 (no)
DE (1) DE69205566T3 (no)
DK (1) DK0576478T4 (no)
ES (1) ES2081102T5 (no)
FI (1) FI107881B (no)
GB (1) GB9105992D0 (no)
GR (1) GR3017884T3 (no)
HK (1) HK1004525A1 (no)
HU (1) HU218025B (no)
IE (1) IE69560B1 (no)
IL (1) IL101290A (no)
MA (1) MA22471A1 (no)
MX (1) MX9201245A (no)
MY (1) MY110086A (no)
NO (1) NO307499B1 (no)
NZ (1) NZ242057A (no)
PL (1) PL170059B1 (no)
PT (1) PT100262B (no)
SA (1) SA92120459B1 (no)
SK (1) SK279190B6 (no)
WO (1) WO1992016231A1 (no)
YU (1) YU28392A (no)
ZA (1) ZA922011B (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
GB9202933D0 (en) * 1992-02-12 1992-03-25 Smithkline Beecham Biolog Vaccines
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
EP0684838A1 (en) * 1993-02-19 1995-12-06 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
DE69405551T3 (de) * 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
CA2163550A1 (en) * 1993-05-25 1994-12-08 Gerald E. Hancock Adjuvants for vaccines against respiratory syncytial virus
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ES2196098T3 (es) * 1994-12-28 2003-12-16 Univ Kentucky Res Found Secuencias anticuerpos anti-idiotipo 3h1 monoclonales relacionadas con el antigeno carcinoembrionico humano.
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US6235280B1 (en) 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US20020041872A1 (en) 1996-04-12 2002-04-11 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6468782B1 (en) 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
US6274143B1 (en) 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
US6692752B1 (en) * 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
EP1104767A1 (en) 1999-11-30 2001-06-06 Stichting Dienst Landbouwkundig Onderzoek Mono- and disaccharide derivatives containing both fatty acid ester and sulfate ester groups
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
JP2008513406A (ja) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
WO2006100111A1 (en) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
EA014107B1 (ru) 2005-12-22 2010-10-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US20100021503A1 (en) 2006-03-30 2010-01-28 Glaxosmithkline Biologicals S.A. Immunogenic composition
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
PL2484375T3 (pl) 2006-09-26 2018-09-28 Infectious Disease Research Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
PT2167121E (pt) 2007-06-26 2015-12-02 Glaxosmithkline Biolog Sa Vacina compreendendo conjugados de polissacáridos capsulares de streptococcus pneumoniae
CA2797937C (en) 2009-05-22 2020-01-14 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
AU2010256461B2 (en) 2009-06-05 2016-03-17 Access To Advanced Health Institute Synthetic glucopyranosyl lipid adjuvants
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2516629B1 (en) * 2009-12-21 2016-04-13 The Brigham and Women's Hospital, Inc. Herpes simplex virus vaccines
CA2856697A1 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
CN103619350A (zh) * 2011-03-11 2014-03-05 麦克马斯特大学 包含组蛋白去乙酰化酶抑制剂的疫苗接种方法
JP6054942B2 (ja) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
US10206996B2 (en) 2011-08-22 2019-02-19 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
US9624273B2 (en) 2011-11-23 2017-04-18 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
CA2897398A1 (en) 2013-01-07 2014-07-10 Biomedical Research Models, Inc. Use of vaccines for the treatment of herpes simplex virus type 2 infections
WO2014172637A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド ヘルペスを処置するための方法および組成物
US11390650B2 (en) 2018-02-05 2022-07-19 The Brigham And Women's Hospital, Inc. Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens
EP4277654A1 (en) 2021-01-18 2023-11-22 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372945A (en) * 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
US5149660A (en) * 1982-02-18 1992-09-22 University Patents, Inc. Diagnostic reagents relating to herpes simplex virus
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
DE3751772T2 (de) * 1986-10-20 1996-12-05 Chiron Corp Impfstoff zur behandlung von hsv
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
JP2955314B2 (ja) * 1988-10-27 1999-10-04 リージェンツ・オブ・ザ・ユニバーシティー・オブ・ミネソタ Ｉｌ―２含有リポソーム免疫アジュバント
US5597573A (en) * 1989-05-04 1997-01-28 Igen, Inc. Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
EP0482068A1 (en) * 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
WO1992002252A1 (en) * 1990-08-01 1992-02-20 Research Corporation Technologies, Inc. The gene encoding equine herpesvirus type 1 glycoprotein d, its gene product, antibodies and their uses
ES2134197T3 (es) * 1990-08-02 1999-10-01 Chiron Corp Vacunas contra el virus del herpes simplex vp16.
GB9106048D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
US5166173A (en) * 1991-01-29 1992-11-24 Genelabs Incorporated Method of treating herpes simplex virus infection
US5196452A (en) * 1991-01-29 1993-03-23 Genelabs Incorporated Macrocyclic anti-viral compound and method
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
MY111880A (en) * 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
DK0761231T3 (da) * 1992-06-25 2000-05-08 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
EP0684838A1 (en) * 1993-02-19 1995-12-06 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
DE69405551T3 (de) * 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
CA2163550A1 (en) * 1993-05-25 1994-12-08 Gerald E. Hancock Adjuvants for vaccines against respiratory syncytial virus

Also Published As

Publication number Publication date
SK279190B6 (sk) 1998-07-08
MA22471A1 (fr) 1992-10-01
IL101290A0 (en) 1992-11-15
DE69205566D1 (en) 1995-11-23
ZA922011B (en) 1993-01-27
KR100224329B1 (ko) 1999-10-15
HU9302645D0 (en) 1994-01-28
ATE129160T1 (de) 1995-11-15
GB9105992D0 (en) 1991-05-08
PT100262A (pt) 1993-06-30
EP0576478B2 (en) 2001-04-18
PT100262B (pt) 2001-05-31
FI934134L (fi) 1993-09-21
MX9201245A (es) 1992-10-01
HU218025B (hu) 2000-05-28
DE69205566T3 (de) 2002-09-05
CN1065997A (zh) 1992-11-11
AP298A (en) 1994-01-14
NO933343D0 (no) 1993-09-20
IL101290A (en) 1996-07-23
IE69560B1 (en) 1996-10-02
CN1201692A (zh) 1998-12-16
BR9205745A (pt) 1994-10-18
NZ242057A (en) 1993-12-23
HK1004525A1 (en) 1998-11-27
NO307499B1 (no) 2000-04-17
US6027730A (en) 2000-02-22
AU1365792A (en) 1992-10-21
CA2106492C (en) 2003-12-09
NO933343L (no) 1993-09-20
ES2081102T5 (es) 2001-09-01
EP0576478A1 (en) 1994-01-05
YU28392A (sh) 1994-11-15
PL170059B1 (pl) 1996-10-31
SA92120459B1 (ar) 2005-06-14
DK0576478T3 (da) 1995-12-04
AP9200368A0 (en) 1992-04-30
CA2106492A1 (en) 1992-09-22
FI107881B (fi) 2001-10-31
CY1936A (en) 1992-03-17
HUT67052A (en) 1995-01-30
MY110086A (en) 1997-12-31
CZ280505B6 (cs) 1996-02-14
EP0576478B1 (en) 1995-10-18
AU650521B2 (en) 1994-06-23
CZ195893A3 (en) 1994-07-13
ES2081102T3 (es) 1996-02-16
DE69205566T2 (de) 1996-04-18
CN1101226C (zh) 2003-02-12
JPH06505727A (ja) 1994-06-30
CN1058191C (zh) 2000-11-08
IE920881A1 (en) 1992-09-23
WO1992016231A1 (en) 1992-10-01
JP3530526B2 (ja) 2004-05-24
GR3017884T3 (en) 1996-01-31
SK94693A3 (en) 1994-05-11
FI934134A0 (fi) 1993-09-21

Similar Documents

Publication Publication Date Title
DK0576478T4 (da) Herpes Simplex-vaccine omfattende HSV-glycoproteingD og 3-deacyleret monophosphoryl-lipid A
DK0689454T4 (da) Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryl-lipid A
DK0633784T3 (da) Hepatitisvacciner indeholdende 3-O-diacyleret monophosphoryl-lipid A
CY2007016I1 (el) Εμβολιο ιου θηλωματος
FI943171L (fi) Ureaasipohjainen rokote Helicobacter-infektiota vastaan
ZA924150B (en) Vaccine for human immunodeficiency virus
FI944052L (fi) Oraalinen rokote
HU9302642D0 (en) Gp 160-derivatives and vaccine containing them or gp-160 itself
IL99851A0 (en) Muramyldipeptide derivatives and influenza vaccine containing them
EP0292293A3 (en) Newcastle disease virus vaccine and method for the applicaton thereof
ITMI913318A0 (it) Preparazioni farmaceutiche a liberazione programmata
HU9203976D0 (en) Vaccine based on modified herpes virus
EP0533263A3 (en) A multivalent hepatitis b virus vaccine
GB9109763D0 (en) Herpes virus vaccine
IL102290A0 (en) Ccv vaccine and its preparation
LV10492A (lv) Vakcina un panemiens HIV(CIV) izraisito saslimsanu arstesanai
RO101948B1 (en) Bivalent inactivated vaccine against paramixo-virosis and newcastle disease at pigeons
NO943251D0 (no) Oral vaksine
ID1028B (id) Vaksin
ZA918588B (en) Novel muramyldipeptide derivatives and influenza vaccine comprising the derivatives
IL94510A0 (en) Influenza vaccine
IL86573A0 (en) Influenza vaccine
NO923242D0 (no) Oral vaksine
GB9105993D0 (en) Vaccines
GB9110067D0 (en) Vaccines